{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006001","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.045396+00:00","generated_at":"2026-06-19T00:30:12.846041+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oragenics enters $5M ATM offering with Ladenburg Thalmann; cash $11.4M, runway through Q3 2023","bullets":["Entered ATM sales agreement with Ladenburg Thalmann to sell up to $5M of common stock; 3% commission.","Cash and equivalents expected ~$11.4M as of Dec 31, 2022; sufficient to fund operations through Q3 2023.","Reverse stock split (1-for-60) completed Jan 20, 2023; post-split shares outstanding ~2.02M.","Plans to file IND for NT-CoV2-1 (Terra CoV-1) in US or Canada and start Phase 1 in H2 2023.","Proceeds to fund pre-clinical development of SARS-CoV-2 vaccine and lantibiotics program."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006001","json":"https://secwatch.observer/filing/0001493152-23-006001.json","markdown":"https://secwatch.observer/filing/0001493152-23-006001.md","text":"https://secwatch.observer/filing/0001493152-23-006001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/0001493152-23-006001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:30:12.846041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55bd082b7d6039e933bab3a6f438fdb4cbcfc5c0","claim":"ORAGENICS INC entered into Sales Agreement with Ladenburg Thalmann & Co. Inc. valued at $5,000,000 (effective 2023-02-24).","evidence_excerpt":"On February 24, 2023, Oragenics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Agent”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock (the “Shares”), depending on market demand, with the Agent acting as the sales agent or principal (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/0001493152-23-006001-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"$5,000,000"},{"label":"Effective","value":"2023-02-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}